Cure8 research brief
CDI during IBD flares may signal higher likelihood of needing advanced therapies within a year. Patients and clinicians may want to consider recent infection history when discussing treatment escalation.
Adults with IBD (Crohn's disease or ulcerative colitis), clinicians managing IBD flares, and researchers studying infection-related drivers of treatment escalation.
A single-center retrospective analysis of 102 IBD patients hospitalized for flares (2020–2024) found gastrointestinal infections in 19% of patients, with CDI representing 58% of infections. Patients with gastrointestinal infection were more likely to be on advanced therapies at 12 months (63% vs.
43%), and CDI was independently associated with biologic use at 12 months (adjusted odds ratio reported by authors). The study suggests that identifying CDI during flares may influence longer-term treatment escalation decisions.
This was an observational, single-center study with a modest sample size and retrospective design, so it can show association but not prove causation.
This is a retrospective, single-center study of hospitalized flare patients; associations do not prove causation and may not generalize to all IBD populations.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study describes how often people newly diagnosed with IBD go on biologic or JAK inhibitor therapy and what happened to them over five years — including hospital visits and surgery — which helps set expectations for...
The study tests a new mechanism (TL1A inhibition) that may reduce inflammation and fibrosis in IBD. Positive phase 2b results suggest duvakitug could become another treatment option if later trials confirm benefit and...
This large national-registry study identifies clinical features linked with needing optimization of biologic or small-molecule therapies in CD and UC. That helps show which patient groups more often require...
